Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study

Manon Cairat*, Anton Pottegård, Morten Olesen, Laure Dossus, Agnès Fournier, Blánaid Hicks

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

37 Downloads (Pure)

Abstract

Low-dose aspirin has been hypothesized to prevent cancer risk by inhibiting platelet aggregation. However, the anti-cancer effect of low-dose aspirin has recently been questioned and its effect on breast cancer development remains unclear. The impact of other antiplatelet drugs on breast cancer risk has rarely been evaluated. Thus, this study aimed to investigate the associations between breast cancer risk and antiplatelet drug use in a nationwide nested case-control study. From the Danish healthcare registries, we identified as cases all women with invasive breast cancer diagnosis between 2001 and 2018 (n = 68 852). The date of diagnosis corresponded to the index date. We matched cases to 10 population controls on age and calendar time, using risk set sampling. Controls were assigned the same index date as their matched case. We used the prescription registry to identify exposure to low-dose aspirin, clopidogrel and dipyridamole. We defined ever use of antiplatelet drugs as at least two prescriptions filled up to 1 year before the index date. We applied conditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals for breast cancer associated with the use of antiplatelet drugs, overall, by breast cancer subtype and by cumulative dose. Twelve percent of women had ever been exposed to low-dose aspirin, 2% to clopidogrel and 2% to dipyridamole. In multivariable models, breast cancer risk was not associated with ever use of low-dose aspirin (OR = 1.00 [0.97-1.03]), clopidogrel (OR = 0.93 [0.87-1.00]), and dipyridamole (OR = 1.02 [0.94-1.10]), compared with never use, and there was no evidence of a dose-response relation. However, we found an inverse association between dipyridamole use and breast cancer risk among women aged <55 years old, with suggestion of a dose-response relationship (OR per 1000 Defined Daily Doses = 0.72 [0.54-0.95]). Associations did not differ by breast cancer histological type, estrogen receptor status or clinical stage at diagnosis. Overall, the findings from this study do not support the use of antiplatelet drugs for breast cancer prevention.

Original languageEnglish
JournalInternational Journal of Cancer
Volume152
Issue number7
Pages (from-to)1337-1347
ISSN0020-7136
DOIs
Publication statusPublished - Apr 2023

Keywords

  • antiplatelet drugs
  • breast cancer
  • low-dose aspirin
  • registries

Fingerprint

Dive into the research topics of 'Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study'. Together they form a unique fingerprint.

Cite this